Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myrcludex B + Tenofovir in Chronic Hepatitis D
NCT03546621Phase 2Completed
- Sponsor
- Hepatera
- Start
- Feb 2016
- Primary completion
- Jan 2018
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of bulevirtide in hepatitis D (HDV) (4 arms), sponsored by Hepatera. Primary endpoint: HDV RNA Response at 24 weeks. Started Feb 2016; status: completed.
02
Drugs
bulevirtide
03
Conditions
hepatitis D (HDV)
Beyond the preview
Go deeper on NCT03546621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03546621.